Sugi Predict

Sugi Predict / Compounds / SCHEMBL17101264

SCHEMBL17101264

SCHEMBL17101264

CCOC(=O)N1CC2CC(=O)CC1C2

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ KMT2A Q03164 3/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ NFKB1 P19838 1/20 0.34
▸ NFKB2 Q00653 1/20 0.34
▸ RELA Q04206 1/20 0.34
▸ TSHR P16473 2/20 0.33
▸ L3MBTL1 Q9Y468 2/20 0.33
▸ MAPT P10636 1/20 0.33
▸ ALOX15 P16050 1/20 0.33
▸ CTNNB1 P35222 1/20 0.33
▸ ELANE P08246 1/20 0.33
▸ CTSG P08311 1/20 0.33
▸ RAB9A P51151 1/20 0.32
▸ NPC1 O15118 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20941851 0.84 TSHR (0.43) ALDH1A1KMT2AMEN1TSHRSMN1; SMN2
SCHEMBL18714318 0.82 HSD11B1 (0.34) KMT2AMEN1
SCHEMBL2653632 0.81 KMT2A (0.40) ALDH1A1KMT2AMEN1TSHRRAB9A
SCHEMBL2078744 0.81 HSD11B1 (0.44) CYP1A2CYP3A4CYP2C19POLB
SCHEMBL2080875 0.79 MEN1 (0.42) ALDH1A1KMT2AMEN1TSHRL3MBTL1
SCHEMBL20942089 0.78 NFKB1 (0.36) ALDH1A1CYP1A2CYP3A4CYP2C19KMT2A
SCHEMBL17039078 0.77 GAA (0.38) ALDH1A1KMT2AMEN1L3MBTL1RAB9A
SCHEMBL17101294 0.76 MEN1 (0.34) KMT2AMEN1
Ethylene SCHEMBL2081141 0.76 MEN1 (0.40) ALDH1A1KMT2AMEN1TSHRL3MBTL1
SCHEMBL1711961 0.74 CHRNA4 (0.47) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3638658-B1 PHARMACEUTICAL COMPOUNDS NXERA PHARMA UK LTD (GB) 2025-10-08 — — EP disclosed
US-12202843-B2 Muscarinic receptor agonists NXERA PHARMA UK LIMITED (GB) 2025-01-21 — — US disclosed
CN-110903306-B Muscarinic receptor agonists 赫普泰雅治疗有限公司 2022-09-23 — — CN disclosed
US-20220048928-A1 MUSCARINIC RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2022-02-17 — — US disclosed
US-20220048928-A1 MUSCARINIC RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2022-02-17 — — US disclosed
US-11034704-B2 Muscarinic receptor agonists NXERA PHARMA UK LIMITED (GB) 2021-06-15 — — US disclosed
US-11034704-B2 Muscarinic receptor agonists NXERA PHARMA UK LIMITED (GB) 2021-06-15 — — US disclosed
EP-3119396-B1 MUSCARINIC RECEPTOR AGONISTS HEPTARES THERAPEUTICS LTD (GB) 2021-05-05 — — EP disclosed
EP-3119396-B1 MUSCARINIC RECEPTOR AGONISTS HEPTARES THERAPEUTICS LTD (GB) 2021-05-05 — — EP disclosed
US-10501483-B2 Enamines and diastereo-selective reduction of enamines ALLERGAN, INC. (US) 2019-12-10 — — US disclosed
US-20180327426-A1 MUSCARINIC RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2018-11-15 — — US disclosed
US-10030035-B2 Muscarinic receptor agonists HEPTARES THERAPEUTICS LIMITED (GB) 2018-07-24 — — US disclosed
US-10030035-B2 Muscarinic receptor agonists HEPTARES THERAPEUTICS LIMITED (GB) 2018-07-24 — — US disclosed
US-10030035-B2 Muscarinic receptor agonists HEPTARES THERAPEUTICS LIMITED (GB) 2018-07-24 — — US disclosed
US-20170096437-A1 MUSCARINIC RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2017-04-06 — — US disclosed
US-20170096437-A1 MUSCARINIC RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2017-04-06 — — US disclosed
US-20170096437-A1 MUSCARINIC RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2017-04-06 — — US disclosed
EP-3119396-A1 MUSCARINIC RECEPTOR AGONISTS Heptares Therapeutics Limited (GB) 2017-01-25 — — EP disclosed
WO-2015140559-A1 MUSCARINIC RECEPTOR AGONISTS HEPTARES THERAPEUTICS LIMITED (GB) 2015-09-24 — — WO disclosed
WO-2015140559-A1 MUSCARINIC RECEPTOR AGONISTS HEPTARES THERAPEUTICS LIMITED (GB) 2015-09-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170096437-A1 MUSCARINIC RECEPTOR AGONISTS CHRM1, CHRM2, CHRM3 ALDH1A1 3572/4885CYP1A2 598/4885CYP3A4 823/4885
US-20220048928-A1 MUSCARINIC RECEPTOR AGONISTS CHRM1, CHRM2, CHRM3 ALDH1A1 3554/4885CYP1A2 597/4885CYP3A4 822/4885
US-12202843-B2 Muscarinic receptor agonists CHRM1, CHRM2, CHRM3 ALDH1A1 3554/4885CYP1A2 597/4885CYP3A4 822/4885
US-20180327426-A1 MUSCARINIC RECEPTOR AGONISTS CHRM1, CHRM2, CHRM3 ALDH1A1 3554/4885CYP1A2 597/4885CYP3A4 822/4885
US-10030035-B2 Muscarinic receptor agonists CHRM1, CHRM2, CHRM3 ALDH1A1 3572/4885CYP1A2 598/4885CYP3A4 823/4885
US-10501483-B2 Enamines and diastereo-selective reduction of enamines ENY2, PNMT, CHRM1 ALDH1A1 3481/4885CYP1A2 720/4885CYP3A4 908/4885
US-11034704-B2 Muscarinic receptor agonists CHRM1, CHRM2, CHRM3 ALDH1A1 3554/4885CYP1A2 597/4885CYP3A4 822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.